[Translation] A randomized, open-label, two-formulation, two-period, two-sequence, single-dose, double-crossover human bioequivalence study of oseltamivir phosphate granules in healthy study participants under fasting and postprandial conditions.

主要目的：以健康研究参与者为试验对象，采用随机、开放、两周期、两序列、双交叉试验设计，考察健康研究参与者空腹及餐后单次口服浙江尖峰药业有限公司生产（浙江尖峰药业有限公司持证）的磷酸奥司他韦颗粒（受试制剂，规格：0.9 g, 按奥司他韦计）与参比制剂磷酸奥司他韦干糖浆（商品名：TAMIFLU®，规格：30g/瓶（3%，每克中以奥司他韦计30mg）；中外製薬株式会社持证）后奥司他韦及其活性代谢物奥司他韦羧酸的体内经时过程，估算其相关药代动力学参数及相对生物利用度，评价奥司他韦空腹及餐后状态下的生物等效性，为受试制剂的生产注册申请提供依据次要目的：评价受试制剂磷酸奥司他韦颗粒（规格：0.9 g，按奥司他韦计）和参比制剂磷酸奥司他韦干糖浆（商品名：TAMIFLU ®，规格：30g/瓶（3%，每克中以奥司他韦计30mg））在健康成年研究参与者中的安全性。

[Translation]

Primary Objective: To investigate the in vivo pharmacokinetic processes of oseltamivir phosphate granules (test formulation, specification: 0.9 g, calculated as oseltamivir) and its active metabolite oseltamivir carboxylic acid after a single oral administration of oseltamivir phosphate granules (manufactured by Zhejiang Jianfeng Pharmaceutical Co., Ltd., licensed by Zhejiang Jianfeng Pharmaceutical Co., Ltd.) and the reference formulation oseltamivir phosphate dry syrup (trade name: TAMIFLU®, specification: 30 g/bottle (3%, 30 mg of oseltamivir per gram); licensed by Chugai Pharmaceutical Co., Ltd.) to healthy study participants, using a randomized, open-label, two-period, two-sequence, two-sequence, double-crossover design. The secondary objective was to evaluate the bioequivalence of oseltamivir in fasting and postprandial states, providing a basis for the production registration application of the test formulation. Secondary Objective: To evaluate the effects of a single oral administration of the test formulation oseltamivir phosphate granules (manufactured by Zhejiang Jianfeng Pharmaceutical Co., Ltd., licensed by Zhejiang Jianfeng Pharmaceutical Co., Ltd.) on oseltamivir phosphate granules (manufactured by Zhejiang Jianfeng Pharmaceutical Co., Ltd., licensed by Zhejiang Jianfeng Pharmaceutical Co., Ltd.) on oseltamivir phosphate dry syrup (trade name: TAMIFLU®, specification: 30 g/bottle (3%, 30 mg of oseltamivir per gram); licensed by Chugai .... Safety of oseltamivir phosphate dry syrup (trade name: TAMIFLU®, specification: 30g/bottle (3%, 30mg oseltamivir per gram)) and reference formulation in healthy adult study participants.

Start Date17 Jan 2026

Sponsor / Collaborator

Zhejiang Jianfeng Pharmaceutical Co., Ltd.

CTR20241796

/ CompletedPhase 1

枸橼酸托法替布缓释片（11 mg）健康人体生物等效性研究

[Translation] Bioequivalence study of tofacitinib citrate extended-release tablets (11 mg) in healthy volunteers

主要目的：本研究以浙江尖峰药业有限公司生产并持有的枸橼酸托法替布缓释片（规格：11 mg）为受试制剂，按生物等效性研究的有关规定，以Pfizer Pharmaceuticals LLC生产的枸橼酸托法替布缓释片（规格：11 mg，商品名：尚杰®/Xeljanz®）为参比制剂，评估受试制剂和参比制剂在空腹/餐后条件下给药后的生物等效性。次要目的：观察受试制剂枸橼酸托法替布缓释片和参比制剂枸橼酸托法替布缓释片（尚杰®/Xeljanz®）在健康受试者中的安全性。

[Translation]

Main purpose: This study used the tofacitinib citrate extended-release tablets (specification: 11 mg) produced and owned by Zhejiang Jianfeng Pharmaceutical Co., Ltd. as the test preparation. According to the relevant regulations of bioequivalence studies, the tofacitinib citrate extended-release tablets (specification: 11 mg, trade name: Shangjie®/Xeljanz®) produced by Pfizer Pharmaceuticals LLC were used as the reference preparation to evaluate the bioequivalence of the test preparation and the reference preparation after administration under fasting/postprandial conditions. Secondary purpose: Observe the safety of the test preparation tofacitinib citrate extended-release tablets and the reference preparation tofacitinib citrate extended-release tablets (Shangjie®/Xeljanz®) in healthy subjects.

Start Date17 Jun 2024

Sponsor / Collaborator

Zhejiang Jianfeng Pharmaceutical Co., Ltd.

CTR20241615

/ CompletedPhase 1

美阿沙坦钾片随机、开放、两周期、两序列、双交叉健康受试者空腹及餐后单次给药人体生物等效性试验

[Translation] A randomized, open-label, two-period, two-sequence, double-crossover bioequivalence study of Asartan Potassium Tablets in healthy subjects after single administration on an empty stomach or after a meal

主要目的：以健康受试者为试验对象，采用随机、开放、两周期、两序列、双交叉试验设计，考察健康受试者空腹及餐后单次口服浙江尖峰药业有限公司生产的美阿沙坦钾片（受试制剂，规格：80mg）与Takeda Ireland Ltd.生产（Takeda Pharma A/S 持证）的美阿沙坦钾片（参比制剂，商品名：易达比®，规格：80mg）后美阿沙坦的体内经时过程，估算其相关药代动力学参数及相对生物利用度，评价其空腹及餐后状态下的生物等效性，为受试制剂的生产注册申请提供依据。次要目的：评价美阿沙坦钾片受试制剂和参比制剂（商品名：易达比®）在健康受试者中的安全性。

[Translation]

Main purpose: With healthy subjects as the test subjects, a randomized, open, two-period, two-sequence, double-crossover design was used to investigate the in vivo time course of mesartan after a single oral administration of mesartan potassium tablets (test preparation, specification: 80 mg) produced by Zhejiang Jianfeng Pharmaceutical Co., Ltd. and mesartan potassium tablets (reference preparation, trade name: Edabi®, specification: 80 mg) produced by Takeda Ireland Ltd. (licensed by Takeda Pharma A/S) to healthy subjects on an empty stomach and after a meal, estimate their relevant pharmacokinetic parameters and relative bioavailability, evaluate their bioequivalence in the fasting and after-meal state, and provide a basis for the production registration application of the test preparation. Secondary purpose: To evaluate the safety of the test preparation and reference preparation of mesartan potassium tablets (trade name: Edabi®) in healthy subjects.

Start Date03 Jun 2024

Sponsor / Collaborator

Zhejiang Jianfeng Pharmaceutical Co., Ltd.

100 Clinical Results associated with Zhejiang Jianfeng Pharmaceutical Co., Ltd.

0 Patents (Medical) associated with Zhejiang Jianfeng Pharmaceutical Co., Ltd.

Literatures (Medical) associated with Zhejiang Jianfeng Pharmaceutical Co., Ltd.

10 Jul 2025·JOURNAL OF MEDICINAL CHEMISTRY

3-Hydroxyquinolin-2-Ones Act as Dual Inhibitors of Ferroptosis and Monoamine Oxidase B: Reducing Alzheimer’s Disease-Related Amyloid Precursor Protein and Hyperphosphorylated Tau In Vivo

Article

Author: Lu, Liwen ; Song, Xiaoxin ; Zhang, Changjun ; He, Jiayan ; Lv, Yangjing ; Fan, Miaoliang ; Jiang, Xiaomeng ; Xie, Yuanyuan ; Guo, Zili

The challenges in the current treatment landscape for Alzheimer's disease (AD) underscore the urgent need for novel therapeutic strategies targeting multiple pathological pathways. Recent studies have implicated iron in ROS-dependent neuronal injury through ferroptosis. Additionally, overexpression of monoamine oxidase B (MAO-B) induces oxidative stress and decreases cognitive function. In this study, we presented the novel dual inhibitors of ferroptosis and MAO-B for AD management, aiming to address both the symptomatic and neurodegenerative aspects of this disease. Compound 21d emerged as a promising candidate, exhibiting potent and selective MAO-B inhibitory activity (IC₅₀ = 87.47 nM, SI > 229), as well as excellent antiferroptosis activity through modulation of the iron metabolic pathway and GSH-GPX4 axis in vitro. Importantly, 21d normalized cognitive and memory impairments in a 3×Tg (APP/Tau/Ps1) AD mouse model and reduced levels of AD-related proteins, including amyloid precursor protein and phosphorylated Tau protein, in the brains of AD mice.

01 May 2023·Bioresource technology

Selective degradation of hemicellulose and lignin for improving enzymolysis efficiency via pretreatment using deep eutectic solvents

Article

Author: Sun, Yuekai ; Zhang, Fengshan ; Fang, Guigan ; Huo Conceptulization, Dan ; Yang, Qiulin ; Zhu, Hongxiang ; Liu, Ying

Deep eutectic solvents (DESs) with different acidity and alkalinity were applied for biomass pretreatment, and the conditions were optimized by response surface methodology. The results showed that lactic acid/betaine hydrochloride had the optimal pretreatment efficiency, where the removal rates of hemicellulose and lignin came up to 89% and 73%, and the enzymolysis efficiency was as high as 92%. Furthermore, eight types of chloride salts with different valence states were introduced into the DESs as the third component. The chloride salts could improve the pretreatment efficiency and positively correlated with the metal valence state. Specifically, AlCl₃ was significantly superior in improving the pretreatment efficiency, where the enzymolysis efficiency reached 96% due to the destruction of crystalline region and the esterification of partial cellulose. Therefore, it is proposed that adding highly valent metal salts to acidic DESs has higher pretreatment and enzymatic efficiency.

12 Sep 2022·Critical reviews in food science and nutritionQ1 · ENGINEERING & TECHNOLOGY

3D food printing: Applications of plant-based materials in extrusion-based food printing

Q1 · ENGINEERING & TECHNOLOGY

Review

Author: Tan, Hui ; Zang, Zhihuan ; Wang, Mingshuang ; Si, Xu ; Li, Dongnan ; Tian, Jinlong ; Bao, Yiwen ; Teng, Wei ; Sun, Xiyun ; Li, Bin ; Liu, Ruihai ; Liang, Qi ; Wang, Jiaxin

As an emerging digital production technology, 3D food printing intends to meet the demand for customized food design, personalized nutrition, simplification of the food supply chain system, and greater food material diversity. Most 3D food printing studies focus on the development of materials for extrusion-based food printing. Plant-based foods are essential for a healthy diet, and they are growing in popularity as their positive effects on human health gain wider recognition. The number of original studies on plant-based printable materials has increased significantly in the past few years. Currently, there is an absence of a comprehensive systematic review on the applications of plant-based materials in extrusion-based food printing. Thus, this review aims to provide a more intuitive overview and guidance for future research on 3D printing of plant-based materials. The requirements, classifications, and binding mechanisms of extrusion-based food printing materials are first summarized. Additionally, notable recent achievements and emerging trends involving the use of plant-based materials in extrusion-based food printing are reviewed across three categories, namely, hot-melt (e.g., chocolate), hydrogel, and soft (e.g., cereal- and fruit/vegetable-based) materials. Finally, the challenges facing 3D food printing technology as well as its future prospects are discussed.

News (Medical) associated with Zhejiang Jianfeng Pharmaceutical Co., Ltd.

17 Feb 2018

·www.bioportfolio.com

Green Tea PolyphenolIndia Market Status and Trend Report 20132023 [Report Updated: 12022018] Prices from USD $2980

Report Summary Green Tea PolyphenolIndia Market Status and Trend Report 20132023 offers a comprehensive analysis on Green Tea Polyphenol industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include: Whole India and Regional Market Size of Green Tea Polyphenol 20132017, and development forecast 20182023 Main market players of Green Tea Polyphenol in India, with company and product introduction, position in the Green Tea Polyphenol market Market status and development trend of Green Tea Polyphenol by types and applications Cost and profit status of Green Tea Polyphenol, and marketing status Market growth drivers and challenges The report segments the India Green Tea Polyphenol market as: India Green Tea Polyphenol Market: Regional Segment Analysis Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 20132023: North India Northeast India East India South India West India India Green Tea Polyphenol Market: Product Type Segment Analysis Consumption Volume, Average Price, Revenue, Market Share and Trend 20132023: Flavanols Anthocyanins Flavonoids Flavonols Phenoliacids India Green Tea Polyphenol Market: Application Segment Analysis Consumption Volume and Market Share 20132023; Downstream Customers and Market Analysis Functional Foods Cosmetics Dietary Supplements Functional Beverages Others India Green Tea Polyphenol Market: Players Segment Analysis Company and Product introduction, Green Tea Polyphenol Sales Volume, Revenue, Price and Gross Margin: DSM Tianjin Jianfeng Natural Products DuPontDanisco Amax NutraSource Naturex Bioserae Prinova FutureCeuticals Indena Ajinomoto OmniChem Natural Specialty Seppic Frutarom In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

100 Deals associated with Zhejiang Jianfeng Pharmaceutical Co., Ltd.

100 Translational Medicine associated with Zhejiang Jianfeng Pharmaceutical Co., Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 08 Nov 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Phase 2

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

JFAN-1001 ( EGFR T790M )	Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma More	IND Approval
Ferroptosis/Monoamine Oxidase B Inhibitors(Zhejiang University of Technology) ( MAO-B )	Alzheimer Disease More	Preclinical
Deoxypodophyllotoxin ( Tubulin )	Advanced Malignant Solid Neoplasm More	Discontinued
C2235	Depressive Disorder More	Discontinued
Ketoprofen Isopropyl Ester ( COXs )	Rheumatoid Arthritis More	Pending

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis